GuidelineCanadian family physician Medecin de famille canadien2011
Update on herpes zoster vaccination: a family practitioner's guide.
Guideline in Canadian family physician Medecin de famille canadien, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial.BMC pediatrics · 2016Trial
- Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study.Vaccines · 2024Article
- Effect of CT-Guided Gasserian Ganglion Block with Local Anesthetics and Steroids on Acute/Subacute Zoster-Related Trigeminal Neuralgia: A Multicenter Retrospective Study.Journal of pain research · 2022Article
- Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.The Journal of infectious diseases · 2017Article
- Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience.Human vaccines & immunotherapeutics · 2017Review
- Approach to preventive care in the elderly.Canadian family physician Medecin de famille canadien · 2016Review
- [Aborder les soins préventifs chez les aînés].Canadian family physician Medecin de famille canadien · 2016Review
- Insights into the role of immunosenescence during varicella zoster virus infection (shingles) in the aging cell model.Oncotarget · 2015Article
- Breast implant extrusion related to Herpesviridae.International journal of surgery case reports · 2015Article
- Herpes zoster vaccine (HZV): utilization and coverage 2009 - 2013, Alberta, Canada.BMC public health · 2014Article
- Herpes zoster vaccination.The Korean journal of pain · 2013Article
- Industry-funded papers.Canadian family physician Medecin de famille canadien · 2011Article
- Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 Update and consensus statement from the Canadian Pain Society.Pain research & managementArticle
- A Prospective Study of Herpes Zoster in Children.Indian journal of dermatologyArticle
- Herpes Zoster Ophthalmicus: A Devastating Disease Coming Back with Vengeance or Finding Its Nemesis?Journal of ophthalmic & vision researchArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo answer frequently asked questions surrounding the use of the new herpes zoster (HZ) vaccine. SOURCES OF INFORMATION: Published results of clinical trials and other studies, recommendations from the Canadian National Advisory Committee on Immunization, and the US Advisory Committee on Immunization Practices; data were also obtained from the vaccine's Health Canada-approved product monograph. MAIN MESSAGE: Herpes zoster results from reactivation of the varicella-zoster virus; postherpetic neuralgia (PHN) is its most common and serious complication. The incidence of PHN after HZ is directly related to age, with 50% of affected individuals older than 60 years experiencing persistent and unrelieved pain. The live virus HZ vaccine reduces the incidence of HZ by about 50% and the occurrence of PHN by two-thirds, with vaccinated individuals experiencing attenuated or shortened symptoms. The vaccine is contraindicated in many immunocompromised patients and might not be effective in patients taking antiviral medications active against the HZ virus. Physicians should be aware of the different recommendations for these groups.
conclusionThe HZ vaccine is a safe and effective preventive measure for reducing the overall burden and severity of HZ in older adults. The vaccine appears to be cost-effective when administered to adults aged 60 years and older.
Indexed as
Identifiers
21998225PMC3192074W2161757015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.